




Statement of stand-alone Financial Results for the quarter and nine months ended 31st December, 2013

Rs. lakhs

PARTICULARS	THREE MONTHS ENDED (REVIEWED)			YEAR-TO-DATE FIGURES (REVIEWED) FOR THE NINE MONTHS PERIOD ENDED ON		YEAR ENDED (AUDITED)
	31-DEC- 2013	30-SEP- 2013	31-DEC- 2012	31-DEC- 2013	31-DEC- 2012	
PART I : STATEMENT OF STAND-ALONE RESULTS						
01. Gross Sales / Income from Operations	16347	14019	13788	44620	41120	54656
Less : Excise Duty	321	375	508	987	1687	2122
Less : Sales Tax	321	269	229	868	823	1101
Net Sales / Income from Operations	15705	13375	13051	42765	38610	51433
02. Other Operating Income	1718	1631	1980	4146	2984	4492
03. TOTAL INCOME FROM OPERATIONS	17423	15006	15031	46911	41594	55925
04. EXPENDITURE						
a) Cost of materials consumed	4485	3755	5064	12111	13289	18063
b) Purchases of stock-in-trade	-	-	55	-	488	558
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-908	-227	-527	-1410	-1436	-2125
d) Employee benefits expense	2492	2214	1878	6911	6449	8536
e) Depreciation and amortization expense	686	656	550	1983	1448	1984
f) Other Expenses	5531	4601	3822	14304	10513	15201
TOTAL EXPENSES	12286	10999	10842	33899	30751	42217
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	5137	4007	4189	13012	10843	13708
06. Other Income	105	177	570	632	991	1194
07. Finance costs	877	957	731	2792	1742	2512
08. Exceptional Items	-	-	541	-	1159	1158
09. Profit / (Loss) from ordinary activities before tax	4365	3227	3487	10852	8933	11232
10. Tax expense, including deferred tax	1123	358	1050	2467	2291	3419
11. Net Profit / Loss (-) from ordinary activities after tax	3242	2869	2437	8385	6642	7813
12. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3307	3137	3137	3307	3137	3137
13. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year						50621
14. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	10.14 10.14	9.15 9.15	7.79 7.79	26.55 26.55	21.29 21.17	25.02 24.91
Part II : Select Information						
15. Public Shareholding:						
a) Number of Shares	15,311,593	13,611,493	13,603,193	15,311,593	13,603,193	13,594,593
b) Percentage of Shareholding	46.30	43.39	43.36	46.30	43.36	43.33
16. Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered –		-	-		-	-
b) Non – encumbered – No. of shares	17,761,481	17,761,581	17,769,881	17,761,481	17,769,881	17,778,481
Percentage (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	53.70	56.61	56.64	53.70	56.64	56.67

Dated at Hyderabad, this, the 13th day of February, 2014.
for and on behalf of the Board of Directors,
NATCO Pharma Limited


V.C. Nannapaneni
Chairman & Managing Director

Status of Investor Complaints as at 31st December, 2013

Pending as on 01-10-2013	Nil
Received during the quarter	96
Resolved during the quarter	96
Pending as on 31-12-2013	Nil



Statement of consolidated Financial Results for the quarter ended 31st December, 2013

Rs. lakhs

PART I : STATEMENT OF CONSOLIDATED RESULTS						
PARTICULARS	THREE MONTHS ENDED (UNREVIEWED / UNAUDITED)			YEAR-TO-DATE FIGURES (UNREVIEWED / UNAUDITED) FOR THE NINE MONTHS PERIOD ENDED ON		YEAR ENDED (AUDITED)
	31-DEC-2013	30-SEP-2013	31-DEC-2012	31-DEC-2013	31-DEC-2012	31-MAR-2013
01. Gross Sales / Income from Operations	19260	16952	16515	53275	49146	65302
Less : Excise Duty	321	390	508	1035	1692	2122
Less : Sales Tax	321	271	229	877	823	1101
Net Sales / Income from Operations	18618	16291	15778	51363	46631	62079
02. Other Operating Income	1718	1631	1983	4146	3039	4322
03. TOTAL INCOME FROM OPERATIONS	20336	17922	17761	55509	49670	66401
04. EXPENDITURE						
a) Cost of materials consumed	6699	6013	7153	18457	19604	17757
b) Purchases of stock-in-trade	-	-	55	-	488	8714
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-908	-227	-527	-1410	-1436	-2191
d) Employee benefits expense	2976	2633	2447	8198	7690	10229
e) Depreciation and amortization expense	770	747	634	2248	1587	2212
f) Other Expenses	6177	5155	4109	16056	11756	16900
TOTAL EXPENSES	15714	14321	13871	43549	39689	53621
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	4622	3601	3890	11960	9981	12780
06. Other Income	127	198	593	675	1055	1241
07. Finance costs	922	1002	758	2920	1808	2631
08. Exceptional Item	-	-	541	-	1159	1158
09. Profit / (Loss) from ordinary activities before tax	3827	2797	3184	9715	8069	10232
10. Tax expense, including deferred tax	1082	371	1061	2453	2323	3644
11. Minority Interest	-243	-266	-136	-610	-308	-599
12. Net Profit / Loss (-) from ordinary activities after tax	2988	2692	2259	7872	6054	7187
13. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3307	3137	3137	3307	3137	3137
14. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year						50217
15. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	9.34 9.34	8.58 8.58	7.20 7.20	24.94 24.94	19.30 19.30	23.01 22.91
16. Public Shareholding:						
a) Number of Shares	15,311,593	13,611,493	13,603,193	15,311,593	13,603,193	13,594,593
b) Percentage of Shareholding	46.30	43.39	43.36	46.30	43.36	43.33
16. Promoters and Promoter Group Shareholding	-	-	-	-	-	-
a) Pledged / Encumbered – No. of shares						
b) Non – encumbered – No. of shares	17,761,481	17,761,581	17,769,881	17,761,481	17,769,881	17,778,481
Percentage (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	53.70	56.61	56.64	53.70	56.64	56.67

The stand-alone results are available on the company's web-site www.natcopharma.co.in. The Board of Directors have recommended an interim dividend of Rs. 5/- per equity share, payable on 6th March, 2014.

Dated at Hyderabad, this, the 13th February, 2014.
for and on behalf of the Board of Directors,
NATCO Pharma Limited



V.C. Nannapaneni
Chairman & Managing Director

Status of Investor Complaints as at 31st December, 2013

Pending as on 01-10-2013	Nil
Received during the quarter	96
Resolved during the quarter	96
Pending as on 31-12-2013	Nil



Report of segment wise revenue, Results and Capital Employed, (Un-audited) under Clause 41 of the Listing Agreement, for the quarter and nine months ended on 31st December, 2013

Rs. lakhs

	THREE MONTHS ENDED			NINE MONTHS ENDED		PREVIOUS ACCOUNTING YEAR ENDED (UN-AUDITED)
	31-DEC-2013	30-SEP-2013	31-DEC-2012	31-DEC-2013	31-DEC-2012	31-MAR-2013
01. Segment Revenue (Net)						
a) Bulk Chemicals	5827	5570	6743	17757	17130	23692
b) Formulations	11667	9616	6982	27771	21795	29367
c) Job Work	343	418	255	956	725	944
d) Unallocated	230	38	1391	2123	2990	3244
Total	18067	15642	15371	48607	42640	57247
Less : Inter-segment Revenue	644	636	340	1696	1046	1322
Net Sales / Income from Operations	17423	15006	15031	46911	41594	55925
02. Segment Results : Profit (+)/Loss (-) before tax and interest						
a) Bulk Chemicals	1509	1051	1614	4077	3986	5527
b) Formulations	5298	4474	2531	11958	9099	12235
c) Job Work	311	332	208	782	599	728
d) Unallocated	204	21	1253	1912	2692	2915
Total	7322	5878	5606	18729	16376	21405
Less : a) Interest	877	957	731	2792	1742	2512
b) Oher unallocable expenditure	2185	1871	1958	5717	6692	8855
c) Unallocable income	105	177	570	632	991	1194
Total Profit Before Tax	4365	3227	3487	10852	8933	11232
03. Capital Employed (Segment Assets - Segment Liabilities)						
a) Bulk Chemicals	40010	37017	37939	40010	37939	36375
b) Formulations	36689	35170	31251	36689	31251	32742
c) Job Work	236	295	48	236	48	94
e) Unallocated (Others)	-3940	-13468	-16688	-3940	-16688	-15453
Total	72995	59014	52550	72995	52550	53758

The above un-audited financial results were reviewed by the Audit Committee, Statutory Auditors and approved by the Board of Directors at a meeting held at Hyderabad, on Thursday, the 13th February, 2014. In respect of non-accounting of minimum alternate tax credit, referred to in the review report, the company will evaluate the position during the current financial year. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary. Exceptional item represents amount written off against a pending legal dispute. Employee benefit expenses for the nine months ended 31st December, 2012 include Rs. 362 lakhs pertaining to stock options vested during the earlier period. The stand-alone results are available on the company's web-site www.natcopharma.co.in. The Board of Directors have recommended an interim dividend of Rs.5 per equity share, (Rs. 4 per equity share during nine months ended 31st December, 2012) payable on 6th March, 2014. During the quarter, the company had allotted, on a preferential basis, 17 lakh equity shares of Rs. 10/- each, at a premium of Rs. 628.40 per share, to CX Securities Limited.

Dated at Hyderabad, this, the 13th day of February, 2014.
for and on behalf of the Board of Directors,
NATCO Pharma Limited

V.C. Nannapaneni
Chairman & Managing Director

Regd. Office: **NATCO** House, Road # 2, Banjara Hills, **Hyderabad : 500 033.**